This blog focuses on the financial pressure many caregivers face while supporting someone living with H-ABC/TUBB4A related leukodystrophy or another rare neurological disease. Beyond medical care, families may carry the cost of travel to specialists, therapies, adaptive equipment, home modifications, medications, insurance deductibles, missed work, reduced hours, and daily caregiving needs that are not always covered by insurance. The central message is that caregivers should not have to navigate the financial side of rare disease alone, and asking for help is a practical step toward protecting both family stability and caregiver well-being.

This blog is written for caregivers supporting someone living with H-ABC/TUBB4A related leukodystrophy or another rare neurological disease. It acknowledges the daily strain of appointments, paperwork, insurance issues, school needs, sleep disruption, financial pressure, and emotional exhaustion, while offering practical first steps for finding support.

Caregivers are encouraged to begin with one urgent need, ask the medical team for a social worker or care coordinator, keep key records in one place, seek respite before a crisis, and connect with therapy, school, insurance, disability, and rare disease resources. The central message is simple: caregivers are often the center of the care system, and they need support too.

Rare disease caregiving is often a quiet, constant kind of work — filled with medical vigilance, disrupted sleep, therapy schedules, appointments, financial strain, emotional uncertainty, and isolation from everyday life.

For families affected by H-ABC/TUBB4A and other rare neurological diseases, the stress reaches beyond logistics; it can affect the body, mind, relationships, and overall well-being of both the person diagnosed and the caregiver.

This blog speaks from one caregiver to another, acknowledging the weight of that responsibility while offering practical, realistic ways to reduce the stress burden and remember that caregivers need care, support, and compassion too.

Connection within the rare disease community plays an important role in supporting both care and research, particularly for conditions such as H-ABC/TUBB4A related leukodystrophy where individuals may be geographically dispersed and limited in number. Advocacy organizations, including the Foundation to Fight H-ABC/TUBB4A, help facilitate these connections by sharing information, supporting participation in registries and studies, and fostering collaboration among families, clinicians, and researchers. Through these coordinated efforts, community engagement contributes to a broader understanding of the condition and helps support a more informed and connected approach to ongoing research and care.

Policies such as the Orphan Drug Act and the Rare Pediatric Disease Priority Review Voucher program play an important role in supporting rare disease research by helping to offset the financial and logistical challenges associated with developing therapies for small patient populations. For conditions such as H-ABC/TUBB4A related leukodystrophy, where the number of identified individuals is limited, these incentives can influence whether research programs move forward and how resources are allocated. While they do not remove the complexities of drug development, they contribute to a framework that makes continued scientific progress more feasible and helps sustain engagement across research, clinical, and industry communities.

Natural history studies play an important role in rare disease research by helping to build a clear understanding of how a condition develops over time. In diseases such as H-ABC/TUBB4A related leukodystrophy, where relatively few individuals have been identified worldwide and clinical presentation can vary, this type of longitudinal observation provides essential context for interpreting change. By documenting how symptoms progress in the absence of treatment, natural history data helps inform clinical trial design, supports the identification of meaningful outcome measures, and contributes to a more structured path toward future therapeutic development.

Hope for Rare Disease Families: Congress Extends Pediatric Drug Incentive Program

Congress has extended an important federal incentive that supports the development of treatments for children with rare diseases. Through the Consolidated Appropriations Act, 2026, lawmakers renewed the Rare Pediatric Disease Priority Review Voucher program through 2029. The program allows the U.S. Food and Drug Administration to award valuable priority review vouchers to companies that successfully develop therapies for rare pediatric diseases.

On the last day of February, Rare Disease Day commands global attention — shining a light on conditions most people will never encounter, yet millions of families confront every single day.

This is not merely a date on the calendar. It is a declaration that rare does not mean invisible. It is a reminder that awareness, while vital, is only the beginning. Real progress demands relentless research, courageous advocacy, and an unwavering commitment to ensure that no life is diminished or delayed simply because a diagnosis is uncommon.

Awareness brings attention, but progress requires strategy. For H-ABC Leukodystrophy, lasting impact depends on investments in data, diagnostics, and collaboration — long before outcomes are visible. This blog outlines how thoughtful philanthropy builds durable progress.

When fewer than 10% of rare diseases have an approved treatment, the issue is not always science. For families affected by H-ABC Leukodystrophy, early-stage research funding determines whether discovery can move forward at all. Understanding this gap changes how impact is created.

Rare disease is not defined by numbers alone. It is a shared system shaped by delayed diagnosis, limited data, and under-built infrastructure — challenges experienced every day by families affected by H-ABC Leukodystrophy. Recognizing this reality changes how progress is made.

The Bridge: For a long time, the story of rare disease was told through the lens of 'scarcity'—too few patients, too much risk, and not enough funding. But we are witnessing a historic pivot. We are moving from an era of managing symptoms to an era of 'curing the incurable.’

After five wonderful years of dedicated service, we share the bittersweet news that Robert “Bob” Ziarko will be retiring from the Foundation’s Board, effective December 2025.

(Image courtesy of Village-News)

Each year, Giving Tuesday offers a global pause—an opportunity to come together, to give, and to make an impact. For rare disease foundations like ours, this day does more than raise funds—it raises visibility, strengthens community, and accelerates progress.

As we approach the end of October, we’re taking a moment to reflect on the incredible momentum our community has built this fall. From fundraising success to scientific progress to new leadership in our advisory team, this season has reminded us of the power of hope, collaboration, and determination. Every step forward is a step we take together- and this fall, we took some big ones.

The Foundation to Fight H-ABC is thrilled to announce the addition of Dr. Eric Mallack and Dr. Josh Bonkowsky to our Advisory Board. These two world-renowned experts bring critical expertise in clinical care, neurogenetics, and leukodystrophy research, strengthening our mission to advance understanding and treatment of H-ABC.

The Foundation to Fight H-abc is recruiting patients living with confirmed diagnosis of H-abc/Tubb4a related Leukodystrophy for a study for drug repurposing.

The process of drug repurposing uses AI to identify the most promising uses for a specific disease using existing drugs. Then, for our study, the top matches are tested against patient RNA to determine what is a viable candidate. Machine learning is very well-suited to identifying these patterns, which a researcher would not be able to at the same magnitude. Because generic, FDA-approved drugs have a known safety profile and are already manufactured and available worldwide, often with substantial data already existing to support the potential new use, drugs can go through an accelerated research process. These drugs can get to patients quickly, in months versus decades, at a low cost of less than 1% of new drug development.

Go to our Resource/Drug Repurposing page for more information and sign up for this study: https://www.h-abc.org/drug-repurposing

In our blog in August we shared that there was a treatment available developed by Nlorem, and the first child was to be treated. Connor has now had three doses and doing well. Join us in supporting the family and helping with their costs as they pave the way for potential new treatment for others waiting.

Connor needs some help

Ben Rosenberg, a vibrant 28-year-old with an unbreakable spirit, was diagnosed in the summer of 2024 with TUBB4a-related Leukodystrophy after a lifetime of uncertainty. This rare neurological condition affects his movement, speech, and balance, but Ben embraces life with a philosophy that inspires everyone around him: "Stay joyful and do the best you can with what you got."

LINK TO BEN’S STORY